A detailed history of Tower Research Capital LLC (Trc) transactions in Immutep LTD stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 83 shares of IMMP stock, worth $164. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83
Previous 2,689 96.91%
Holding current value
$164
Previous $6,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.87 - $3.23 $4,873 - $8,417
-2,606 Reduced 96.91%
83 $0
Q1 2024

May 15, 2024

BUY
$2.11 - $2.89 $5,462 - $7,482
2,589 Added 2589.0%
2,689 $6,000
Q4 2023

Feb 13, 2024

BUY
$1.76 - $2.49 $112 - $159
64 Added 177.78%
100 $0
Q3 2023

Nov 14, 2023

BUY
$1.75 - $2.37 $63 - $85
36 New
36 $0
Q1 2023

May 09, 2023

SELL
$1.63 - $2.06 $11,892 - $15,029
-7,296 Reduced 98.58%
105 $0
Q4 2022

Feb 10, 2023

SELL
$1.6 - $2.53 $12,480 - $19,734
-7,800 Reduced 51.31%
7,401 $13,000
Q3 2022

Nov 10, 2022

BUY
$1.56 - $2.29 $8,561 - $12,567
5,488 Added 56.5%
15,201 $24,000
Q2 2022

Aug 15, 2022

BUY
$1.96 - $3.09 $19,037 - $30,013
9,713 New
9,713 $20,000
Q1 2022

May 12, 2022

SELL
$2.3 - $3.61 $2,617 - $4,108
-1,138 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.09 - $4.81 $3,516 - $5,473
1,138 New
1,138 $4,000
Q3 2021

Nov 15, 2021

SELL
$3.17 - $4.39 $3,861 - $5,347
-1,218 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.02 - $5.21 $3,678 - $6,345
1,218 New
1,218 $5,000
Q1 2020

May 15, 2020

SELL
$0.72 - $3.03 $169 - $715
-236 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$1.6 - $1.9 $99 - $117
62 Added 35.63%
236 $0
Q3 2019

Nov 05, 2019

BUY
$1.27 - $1.78 $220 - $309
174 New
174 $0

Others Institutions Holding IMMP

About IMMUTEP Ltd


  • Ticker IMMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,000
  • Market Cap $172M
  • Description
  • Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...
More about IMMP
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.